We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Continued Use of Effective Contraception After Use of Emergency Contraception

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02078414
First Posted: March 5, 2014
Last Update Posted: November 26, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Helena Kopp Kallner, Karolinska Institutet
  Purpose
Women using an emergency contraceptive method must use back up protection for 1-2 weeks depending on method. The Copper-IUD is the most effective emergency contraceptive method. The investigators wish to explore if women choosing the Cooper IUD have a higher frequency of use of an effective contraceptive method 3 months and 6 months after the use of an emergency contraceptive method than women who choose to use the emergency contraceptive pill EllaOne (ulipristal acetate).

Condition
Emergency Contraception Contraception Reproductive Health

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Helena Kopp Kallner, Karolinska Institutet:

Primary Outcome Measures:
  • Use of an effective contraceptive method [ Time Frame: 6 months after emergency contraceptive use ]
    Use of pill, patch, ring, IUD, IUS, or injection 6 months after use of emergency contraceptive method


Enrollment: 7
Study Start Date: March 2014
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Ulipristal acetate
Women choosing EllaOne as emergency contraception
Copper IUD
Women choosing copper IUD as emergency contraception

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women without contraception or with a failed contraceptive method seeking emergency contraception
Criteria

Inclusion Criteria:

  • women over 18 years
  • eligible for all emergency contraception

Exclusion Criteria:

  • previous conisation
  • known stenosis of the cervix
  • signs of ongoing genital infection
  • known uterine anomaly
  • Known bleeding disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02078414


Locations
Sweden
RFSU clinic
Stockholm, Sweden
Sponsors and Collaborators
Karolinska Institutet
  More Information

Responsible Party: Helena Kopp Kallner, Consultant Obstetrics and Gynecology, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT02078414     History of Changes
Other Study ID Numbers: RFSU1
First Submitted: March 3, 2014
First Posted: March 5, 2014
Last Update Posted: November 26, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Emergencies
Disease Attributes
Pathologic Processes